Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to stall lung cancer

NCT ID NCT03519971

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage III lung cancer that cannot be removed by surgery. About 328 participants will receive either durvalumab or a placebo alongside their chemo and radiation. The main goal is to see if the combination delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Durvalumab (an immunotherapy drug) given with chemotherapy and radiation
What this could lead to
If it works, this could offer a new treatment option that helps control stage III lung cancer for longer without the cancer growing.
What could go wrong
This is still being tested, and results may not show a clear benefit. Immunotherapy can cause side effects like inflammation in healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

328 people

The number who actually took part.

Started

Mar 2018

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Principal inclusion criteria : * Subjects with histologically- or cytologically-documented NSCLC * Locally advanced, unresectable (Stage III) NSCLC * World Health Organisation (WHO) performance status 0-1 * At least one measurable lesion, not previously irradiated * Must have a life expectancy of at least 12 weeks at randomization Principal exclusion criteria : * Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs. * Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines. * History of allogeneic organ transplantation * Active or prior documented autoimmune or inflammatory disorders * Uncontrolled intercurrent illness * History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency * Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus * Mixed small cell and NSCLC histology * Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling * Known allergy or hypersensitivity to any of the IPs or any of the IP excipients. * Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Research Site

    Barretos, 14784-400, Brazil

  • Research Site

    Curitiba, 81520-060, Brazil

  • Research Site

    Florianópolis, 88034-000, Brazil

  • Research Site

    Fortaleza, 60336-045, Brazil

  • Research Site

    Porto Alegre, 90035-003, Brazil

  • Research Site

    Porto Alegre, 90610-000, Brazil

  • Research Site

    Porto Alegre, 91350-200, Brazil

  • Research Site

    Ribeirão Preto, 14021-636, Brazil

  • Research Site

    Ribeirão Preto, 14048900, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    Brno, 656 53, Czechia

  • Research Site

    Ostrava, 703 00, Czechia

  • Research Site

    Prague, 128 08, Czechia

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Győr, 9024, Hungary

  • Research Site

    Gyula, 5700, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Bangalore, 560068, India

  • Research Site

    Chennai, 600035, India

  • Research Site

    Gurgaon, 122001, India

  • Research Site

    Karamsad, 388325, India

  • Research Site

    Mumbai, 400053, India

  • Research Site

    Nashik, 422005, India

  • Research Site

    New Delhi, 110063, India

  • Research Site

    Vadodara, 390007, India

  • Research Site

    Bunkyō City, 113-8603, Japan

  • Research Site

    Fukuoka, 812-8582, Japan

  • Research Site

    Kōtoku, 135-8550, Japan

  • Research Site

    Kyoto, 606-8507, Japan

  • Research Site

    Nagoya, 464-8681, Japan

  • Research Site

    Sayama, 589-8511, Japan

  • Research Site

    Sendai, 980-0873, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Aguascalientes, 20230, Mexico

  • Research Site

    Guadalajara, 44280, Mexico

  • Research Site

    Mexico City, 0 3100, Mexico

  • Research Site

    Mérida, 97134, Mexico

  • Research Site

    México, 04700, Mexico

  • Research Site

    Orizaba, 94300, Mexico

  • Research Site

    La Libertad, 13013, Peru

  • Research Site

    Lima, 15033, Peru

  • Research Site

    Lima, L27, Peru

  • Research Site

    Lima, LIMA 27, Peru

  • Research Site

    Lima, LIMA 34, Peru

  • Research Site

    Lima, LIMA 41, Peru

  • Research Site

    Cebu City, 6000, Philippines

  • Research Site

    City of Taguig, 1634, Philippines

  • Research Site

    Iloilo City, 5000, Philippines

  • Research Site

    Makati, 1229, Philippines

  • Research Site

    Manila, 1015, Philippines

  • Research Site

    Quezon City, Philippines

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Elblag, 02-300, Poland

  • Research Site

    Gdansk, 80-952, Poland

  • Research Site

    Olsztyn, 10-228, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Chelyabinsk, 454087, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 115533, Russia

  • Research Site

    Moscow, 125367, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Rostov-on-Don, 344037, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Busan, 48108, South Korea

  • Research Site

    Chungcheongbuk-do, 28644, South Korea

  • Research Site

    Gyeongsangnam-do, 52727, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Hat Yai, 90110, Thailand

  • Research Site

    Khon Kaen, 40002, Thailand

  • Research Site

    Mueang, 50200, Thailand

  • Research Site

    Ankara, 06230, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Antalya, 07059, Turkey (Türkiye)

  • Research Site

    Diyarbakır, 21280, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Izmir, 35100, Turkey (Türkiye)

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hanoi, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.